ORCL vs PFE: Which Is the Better Buy?
Side-by-side comparison of Oracle Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-18.
Oracle Corporation · Technology
$175.08
+24.7% upside to fair value
Grade B
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction
Grade B+
QuantHub Verdict
PFE has more upside to fair value
(+30.1%).
PFE trades at a lower forward P/E
(9.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ORCL |
PFE |
| Current Price |
$175.08 |
$26.91 |
| Fair Value Estimate |
$218.26 |
$35.00 |
| Upside to Fair Value |
+24.7%
|
+30.1%
|
| Market Cap |
$503.5B |
$153.0B |
| Forward P/E |
30.8x
|
9.5x
|
| EV / EBITDA |
21.4x
|
13.8x
|
| Price / Sales |
7.9x
|
2.4x
|
| Price / FCF |
-20.4x
|
16.8x
|
| Revenue Growth YoY |
+7.0%
|
-1.6%
|
| Gross Margin |
66.4%
|
70.3%
|
| Operating Margin |
30.8%
|
24.7%
|
| Return on Equity |
57.4%
|
9.0%
|
| Dividend Yield |
0% |
6.4% |
| FCF Yield |
—
|
5.9%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Oracle Corporation is a leading technology company specializing in software infrastructure, with a dominant Cloud and License Business segment generating 85.8% of its $57.4 billion revenue in fiscal 2025. The company benefits from a durable competitive moat driven by decades of leadership continuity, aggressive M&A history, and a strong position in enterprise software and cloud services. Despite …
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
| Metric |
ORCL |
PFE |
| Zone Low |
$163.69 |
$25.00 |
| Zone High |
$185.52 |
$29.00 |
| In Buy Zone? |
Yes
|
Yes
|